Reviews in Endocrine and Metabolic Disorders

Open Access 15-03-2025 | Acromegaly

Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries

Authors: Luigi Demarchis, Sabrina Chiloiro, Antonella Giampietro, Laura De Marinis, Antonio Bianchi, Maria Fleseriu, Alfredo Pontecorvi

Published in: Reviews in Endocrine and Metabolic Disorders

Abstract

Acromegaly is a rare condition, and often diagnosis is delayed by several years, for most patients. Acromegaly is characterized by short and long-term respiratory, cardiovascular and metabolic comorbidities, with possible impact on mortality. In the last two decades, life expectancy has progressively increased in part due to a reduction in biochemically active disease, multidisciplinary treatment approaches and a reduction in complications, and the availability of new drugs. Of note, a leading cause of mortality, cardiovascular comorbidity, has been replaced by cancer(s). As such, neoplasms more frequently observed (colon, thyroid, breast, prostate, and stomach) in patients with acromegaly are receiving increased attention. Chronic exposure to increased growth hormone serum levels may contribute to an increase in the occurrence and progression of cancers. Various efforts have been made to determine the pathogenetic mechanisms involved. However, there are no clear medical-related societal agreement(s) in relation to screening methods or timing regarding neoplasm(s) diagnosis in patients with acromegaly. Additionally, independent and dependent risk factor data in patients with acromegaly is lacking. International/national registries could help lay the groundwork to better study the impact of cancer(s) in patients with acromegaly and subsequently lead to and validate the most appropriate diagnostic and therapeutic path forward.

Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937–50. https://doi.org/10.1056/NEJMra1810772.CrossRefPubMed

Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804–26. https://doi.org/10.1016/S2213-8587(22)00244-3.CrossRefPubMed

Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19(3):262–7. https://doi.org/10.1007/s11102-015-0701-2.CrossRefPubMedPubMedCentral

Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, Ferraù F, Gianfrilli D, Cozzolino A, Cristina De Martino M, Gatto F, Barone-Adesi F, Cannavò S, Trifirò G. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185(2):251–63. https://doi.org/10.1530/EJE-21-0216.CrossRefPubMed

Matsubayashi K, Kawakami K. Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocr J. 2020;67(10):997–1006. https://doi.org/10.1507/endocrj.EJ20-0129.CrossRefPubMed

Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9. https://doi.org/10.1007/s11102-016-0754-x.CrossRefPubMed

Park KH, Lee EJ, Seo GH, Ku CR. Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly. J Clin Endocrinol Metab. 2020;105(4):dgz17. https://doi.org/10.1210/clinem/dgz317.CrossRef

Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59–71. https://doi.org/10.1530/EJE-18-0255.CrossRefPubMed

Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667–74. https://doi.org/10.1210/jc.2003-031199.CrossRefPubMed

10.

Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, JohannssonBeckers GA, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Clinical biology of the pituitary adenoma. Endocr Rev. 2022;43(6):1003–37. https://doi.org/10.1210/endrev/bnac010.CrossRefPubMedPubMedCentral

11.

Ritvonen E, Löyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, Kauppinen-Mäkelin R, Schalin-Jäntti C. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer. 2016;23(6):469–80. https://doi.org/10.1530/ERC-16-0106.CrossRefPubMed

12.

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S; Acromegaly Consensus Group. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024 Feb;27(1):7–22. https://doi.org/10.1007/s11102-023-01360-1. Epub 2023 Nov 3. Erratum in: Pituitary. 2024 Feb;27(1):88. https://doi.org/10.1007/s11102-023-01373-w.

13.

Amodru V, Sahakian N, Piazzola C, Appay R, Graillon T, Cuny T, Morange I, Albarel F, Vermalle M, Regis J, Dufour H, Brue T, Castinetti F. Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades. Pituitary. 2024;27(3):294–302. https://doi.org/10.1007/s11102-024-01387-y.CrossRefPubMed

14.

Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr Rev. 2019;40(1):268–332. https://doi.org/10.1210/er.2018-00115.CrossRefPubMed

15.

Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, Swearingen B, Nachtigall LB. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):e532–43. https://doi.org/10.1210/clinem/dgz187.CrossRefPubMed

16.

Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab. 2008;93(6):2035–41. https://doi.org/10.1210/jc.2007-2149.CrossRefPubMed

17.

Ioachimescu AG, Handa T, Goswami N, Pappy AL 2nd, Veledar E, Oyesiku NM. Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients. Endocrine. 2020;67(2):423–32. https://doi.org/10.1007/s12020-019-02123-4.CrossRefPubMed

18.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–53. https://doi.org/10.1016/S0140-6736(04)16044-3.CrossRefPubMed

19.

Danilowicz K, Sosa S. Acromegaly and cancer: an update. Arch Med Res. 2023;54(8): 102914. https://doi.org/10.1016/j.arcmed.2023.102914.CrossRefPubMed

20.

Freda PU, Bruce JN, Jin Z, Kostadinov J, Khandji AG, Cremers S, Post KD. Prospective, longitudinal study of cancer predictors and rates in a New York City cohort of 598 patients with acromegaly. J Clin Endocrinol Metab. 2024;10:dgae469. https://doi.org/10.1210/clinem/dgae469.CrossRef

21.

Petroff D, Tönjes A, Grussendorf M, Droste M, Dimopoulou C, Stalla G, Jaursch-Hancke C, Mai M, Schopohl J, Schöfl C. The incidence of cancer among acromegaly patients: results from the German acromegaly registry. J Clin Endocrinol Metab. 2015;100(10):3894–902. https://doi.org/10.1210/jc.2015-2372.CrossRefPubMed

22.

Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–46. https://doi.org/10.1530/eje.0.1510439.CrossRefPubMed

23.

Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, Chabre O, François P, Bertherat J, Cortet-Rudelli C, Chanson P, French Acromegaly Registry Group. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176(5):645–55. https://doi.org/10.1530/EJE-16-1064.CrossRefPubMed

24.

Guevara-Aguirre J, Peña G, Acosta W, Pazmiño G, Saavedra J, Soto L, Lescano D, Guevara A, Gavilanes AWD. Cancer in growth hormone excess and growth hormone deficit. Endocr Relat Cancer. 2023;30(10): e220402. https://doi.org/10.1530/ERC-22-0402.CrossRefPubMed

25.

Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001;86(7):2929–34. https://doi.org/10.1210/jcem.86.7.7635.CrossRefPubMed

26.

Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2): 101264. https://doi.org/10.1016/j.beem.2019.02.001.CrossRefPubMed

27.

Găloiu S, Toma ID, Tănasie DI, Bărbulescu A, Baciu I, Niculescu DA, Trifănescu RA, Căpăţînă C, Radian Ş, Poiană C. High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne). 2024;21(15):1348972. https://doi.org/10.3389/fendo.2024.1348972.CrossRef

28.

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667–78. https://doi.org/10.1007/s11154-020-09588-z.CrossRefPubMedPubMedCentral

29.

Brue T, Rahabi H, Barry A, Barlier A, Bertherat J, Borson-Chazot F, Castinetti F, Cazabat L, Chabre O, Chevalier N, Christin-Maitre S, Cortet C, Drui D, Kamenicky P, Lançon C, Lioté F, Pellegrini I, Reynaud R, Salenave S, Tauveron I, Touraine P, Vantyghem MC, Vergès B, Vezzosi D, Villa C, Raverot G, Coutant R, Chanson P, Albarel F. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP). Ann Endocrinol (Paris). 2023;84(6):697–710. https://doi.org/10.1016/j.ando.2023.08.003.CrossRefPubMed

30.

Boguszewski CL, Boguszewski MCDS. Growth Hormone’s Links to Cancer. Endocr Rev. 2019;40(2):558–74. https://doi.org/10.1210/er.2018-00166.CrossRefPubMed

31.

Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ, Laurberg P, Pedersen L, Dekkers OM, Sørensen HT, Jørgensen JO. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175(3):181–90. https://doi.org/10.1530/EJE-16-0117.CrossRefPubMed

32.

Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23(38):6365–78. https://doi.org/10.1038/sj.onc.1207751.CrossRefPubMed

33.

Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol. 2016;29:77–89. https://doi.org/10.1016/j.coph.2016.07.005.CrossRefPubMedPubMedCentral

34.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34(35):4270–6. https://doi.org/10.1200/JCO.2016.67.4283.CrossRefPubMedPubMedCentral

35.

Cuttica CM, Briata IM, DeCensi A. Novel treatments for obesity: implications for cancer prevention and treatment. Nutrients. 2023;15(17):3737. https://doi.org/10.3390/nu15173737.CrossRefPubMedPubMedCentral

36.

Tarasiuk A, Mosińska P, Fichna J. The mechanisms linking obesity to colon cancer: An overview. Obes Res Clin Pract. 2018;12(3):251–9. https://doi.org/10.1016/j.orcp.2018.01.005.CrossRefPubMed

37.

Franchini F, Palatucci G, Colao A, Ungaro P, Macchia PE, Nettore IC. Obesity and Thyroid Cancer Risk: An Update. Int J Environ Res Public Health. 2022;19(3):1116. https://doi.org/10.3390/ijerph19031116.CrossRefPubMedPubMedCentral

38.

Brown KA. Metabolic pathways in obesity-related breast cancer. Nat Rev Endocrinol. 2021;17(6):350–63. https://doi.org/10.1038/s41574-021-00487-0.CrossRefPubMedPubMedCentral

39.

Saha A, Kolonin MG, DiGiovanni J. Obesity and prostate cancer - microenvironmental roles of adipose tissue. Nat Rev Urol. 2023;20(10):579–96. https://doi.org/10.1038/s41585-023-00764-9.CrossRefPubMed

40.

Jang HN, Kim YH, Kim JH. Diabetes mellitus predicts weight gain after surgery in patients with acromegaly. Front Endocrinol (Lausanne). 2022;9(13): 854931. https://doi.org/10.3389/fendo.2022.854931.CrossRef

41.

Xie T, Ding H, Xia M, Zhang X, Sun W, Liu T, Gu Y, Sun C, Hu F. Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly. Endocrine. 2018;62(3):552–9. https://doi.org/10.1007/s12020-018-1742-x.CrossRefPubMed

42.

Brummer RJ, Lönn L, Kvist H, Grangård U, Bengtsson BA, Sjöström L. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur J Clin Invest. 1993;23(4):199–205. https://doi.org/10.1111/j.1365-2362.1993.tb00762.x.CrossRefPubMed

43.

Kuker AP, Shen W, Jin Z, Singh S, Chen J, Bruce JN, Freda PU. Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly. J Endocr Soc. 2021;5(3):bvab004. https://doi.org/10.1210/jendso/bvab004.CrossRefPubMedPubMedCentral

44.

Plöckinger U, Reuter T. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. Eur J Endocrinol. 2008;158(4):467–71. https://doi.org/10.1530/EJE-07-0637.CrossRefPubMed

45.

Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–77. https://doi.org/10.1210/er.2008-0027.CrossRefPubMed

46.

Rudman Y, Fleseriu M, Dery L, Masri-Iraqi H, Sasson L, Shochat T, Kushnir S, Shimon I, Akirov A. Endogenous Cushing’s syndrome and cancer risk. Eur J Endocrinol. 2024;191(2):223–31. https://doi.org/10.1093/ejendo/lvae098.CrossRefPubMed

47.

Guo X, Zhang R, Zhang D, Wang Z, Gao L, Yao Y, Deng K, Bao X, Feng M, Xu Z, Yang Y, Lian W, Wang R, Ma W, Xing B. Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 Patients. Front Endocrinol (Lausanne). 2022;26(12): 807054. https://doi.org/10.3389/fendo.2021.807054.CrossRef

48.

Ceccato F, Lizzul L, Zilio M, Barbot M, Denaro L, Emanuelli E, Alessio L, Rolma G, Manara R, Saller A, Boscaro M, Scaroni C. Medical treatment for acromegaly does not increase the risk of central adrenal insufficiency: a long-term follow-up study. Horm Metab Res. 2016;48(8):514–9. https://doi.org/10.1055/s-0042-103933.CrossRefPubMed

49.

Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Hypopituitarism. Lancet. 2024;403(10444):2632–48. https://doi.org/10.1016/S0140-6736(24)00342-8.CrossRefPubMed

50.

Mazziotti G, Formenti AM, Frara S, Roca E, Mortini P, Berruti A, Giustina A. Management of endocrine disease: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol. 2017;177(5):R231–48. https://doi.org/10.1530/EJE-17-0154.CrossRefPubMed

51.

Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91(10):3954–61. https://doi.org/10.1210/jc.2006-0524.CrossRefPubMed

52.

Chiloiro S, Vicari A, Mongelli G, Costanza F, Giampietro A, Mattogno PP, Lauretti L, Olivi A, De Marinis L, Doglietto F, Bianchi A, Pontecorvi A. Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy. Rev Endocr Metab Disord. 2024;25(5):855–73. https://doi.org/10.1007/s11154-024-09898-6.CrossRefPubMedPubMedCentral

53.

Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119(12):1198–208. https://doi.org/10.7326/0003-4819-119-12-199312150-00007.CrossRefPubMed

54.

Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol. 1989;98(4):1287–95. https://doi.org/10.1111/j.1476-5381.1989.tb12676.x.CrossRefPubMedPubMedCentral

55.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. https://doi.org/10.1126/science.1203486.CrossRefPubMed

56.

Chiloiro S, De Marinis L. The immune microenviroment in somatotropinomas: from biology to personalized and target therapy. Rev Endocr Metab Disord. 2023;24(2):283–95. https://doi.org/10.1007/s11154-022-09782-1.CrossRefPubMedPubMedCentral

57.

Chiloiro S, Giampietro A, Gessi M, Lauretti L, Mattogno PP, Cerroni L, Carlino A, De Alessandris QG, Olivi A, Rindi G, Pontecorvi A, De Marinis L, Doglietto F, Bianchi A. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs. J Neuroendocrinol. 2023;35(4): e13263. https://doi.org/10.1111/jne.13263.CrossRefPubMed

58.

Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, Bima C, Bracaccia ME, Lugli F, Lauretti L, Anile C, Gessi M, Colosimo C, Rindi G, Pontecorvi A, Korbonits M, De Marinis L. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2020;67(3):651–8. https://doi.org/10.1007/s12020-019-02145-y.CrossRefPubMed

59.

Chiloiro S, Moroni R, Giampietro A, Angelini F, Gessi M, Lauretti L, Mattogno PP, Calandrelli R, Tartaglione T, Carlino A, Gaudino S, Olivi A, Rindi G, De Marinis L, Pontecorvi A, Doglietto F, Bianchi A. The multibiomarker acro-time score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort. J Clin Endocrinol Metab. 2024;109(5):1341–50. https://doi.org/10.1210/clinem/dgad673.CrossRefPubMed

60.

Sørensen GV, Cronin-Fenton DP, Sørensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21. https://doi.org/10.1186/bcr3106.CrossRefPubMedPubMedCentral

61.

Oh TK, Song IA. Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea. Cancer Prev Res (Phila). 2020;13(12):1017–26. https://doi.org/10.1158/1940-6207.CAPR-20-0161.CrossRefPubMed

62.

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378(9785):31–40. https://doi.org/10.1016/S0140-6736(11)60679-X.CrossRefPubMed

63.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 9;387(10027):1513–1530. https://doi.org/10.1016/S0140-6736(16)00618-8. Erratum in: Lancet. 2017 Feb 4;389(10068):e2. https://doi.org/10.1016/S0140-6736(16)32060-8.

64.

Kim DS, Scherer PE. Obesity, diabetes, and increased cancer progression. Diabetes Metab J. 2021;45(6):799–812. https://doi.org/10.4093/dmj.2021.0077.CrossRefPubMedCentral

65.

Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D, Rizos EC, Monori G, Ward HA, Kyrgiou M, Gunter MJ, Tsilidis KK. Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1218–28. https://doi.org/10.1158/1055-9965.EPI-20-1245.CrossRefPubMedPubMedCentral

66.

Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20(11):629–44. https://doi.org/10.1038/s41568-020-0295-5.CrossRefPubMed

67.

Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–64. https://doi.org/10.1001/jama.2008.824.CrossRefPubMedPubMedCentral

68.

Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44. https://doi.org/10.2337/dc12-0002.CrossRefPubMedPubMedCentral

69.

Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, Jørgensen JOL, Ragnarsson O, Ferone D, Johannsson G. Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol. 2024;20(9):541–52. https://doi.org/10.1038/s41574-024-00993-x.CrossRefPubMed

70.

Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect. 2014;3(2):93–8. https://doi.org/10.1530/EC-14-0021.CrossRefPubMedPubMedCentral

71.

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52. https://doi.org/10.1210/er.2002-0022.CrossRefPubMed

72.

Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182(6):523–31. https://doi.org/10.1530/EJE-20-0019.CrossRefPubMed

73.

Colao A, Grasso LFS, Di Cera M, Thompson-Leduc P, Cheng WY, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J Endocrinol Invest. 2020;43(4):529–38. https://doi.org/10.1007/s40618-019-01138-y.CrossRefPubMed

74.

Moustaki M, Paschou SA, Xekouki P, Kotsa K, Peppa M, Psaltopoulou T, Kalantaridou S, Vryonidou A. Secondary diabetes mellitus in acromegaly. Endocrine. 2023;81(1):1–15. https://doi.org/10.1007/s12020-023-03339-1.CrossRefPubMedPubMedCentral

75.

Biagetti B, Aulinas A, Casteras A, Pérez-Hoyos S, Simó R. HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary. 2021;24(2):146–58. https://doi.org/10.1007/s11102-020-01092-6.CrossRefPubMed

76.

Mori K, Iwasaki Y, Kawasaki-Ogita Y, Honjo S, Hamamoto Y, Tatsuoka H, Fujimoto K, Ikeda H, Wada Y, Takahashi Y, Takahashi J, Koshiyama H. Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest. 2013;36(10):853–9. https://doi.org/10.3275/8964.CrossRefPubMed

77.

Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, Nielsen EH, Andersen M, Feldt-Rasmussen U, Dekkers OM, Sørensen HT, Jørgensen JOL. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. J Clin Endocrinol Metab. 2018;103(6):2182–8. https://doi.org/10.1210/jc.2017-02457.CrossRefPubMed

78.

Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Ferone D, Montini M, Bondanelli M, De Menis E, Martini C, Puxeddu E, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Peraga G, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Berton A, Serban AL, Baldelli R, Fatti LM, Colao A, Arosio M, Italian Study Group of Acromegaly. Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr Relat Cancer. 2017;24(9):495–504. https://doi.org/10.1530/ERC-16-0553.CrossRefPubMed

79.

Wolinski K, Stangierski A, Dyrda K, Nowicka K, Pelka M, Iqbal A, Car A, Lazizi M, Bednarek N, Czarnywojtek A, Gurgul E, Ruchala M. Risk of malignant neoplasms in acromegaly: a case-control study. J Endocrinol Invest. 2017;40(3):319–22. https://doi.org/10.1007/s40618-016-0565-y.CrossRefPubMed

80.

Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4081–6. https://doi.org/10.1210/jc.2004-1381.CrossRefPubMed

81.

Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008;55(1):67–71. https://doi.org/10.1507/endocrj.k07e-010.CrossRefPubMed

82.

Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395–400. https://doi.org/10.1023/a:1015713732717.CrossRefPubMed

83.

Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8):2730–4. https://doi.org/10.1210/jcem.83.8.5007.CrossRefPubMed

84.

Heisser T, Hoffmeister M, Tillmanns H, Brenner H. Impact of demographic changes and screening colonoscopy on long-term projection of incident colorectal cancer cases in Germany: A modelling study. Lancet Reg Health Eur. 2022;30(20): 100451. https://doi.org/10.1016/j.lanepe.2022.100451.CrossRef

85.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E, Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3.CrossRefPubMedPubMedCentral

86.

Jhun BH, Meinkoth JL, Leitner JW, Draznin B, Olefsky JM. Insulin and insulin-like growth factor-I signal transduction requires p21ras. J Biol Chem. 1994;269(8):5699–704.CrossRefPubMed

87.

Chesnokova V, Zonis S, Apaydin T, Barrett R, Melmed S. Non-pituitary growth hormone enables colon cell senescence evasion. Aging Cell. 2024;23(8): e14193. https://doi.org/10.1111/acel.14193.CrossRefPubMedPubMedCentral

88.

Chesnokova V, Zonis S, Zhou C, Recouvreux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, Uhart M, Melmed S. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3250–9. https://doi.org/10.1073/pnas.1600561113. Epub 2016 May 25. Erratum in: Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5251. https://doi.org/10.1073/pnas.1612785113.

89.

Apaydin T, Zonis S, Zhou C, Valencia CW, Barrett R, Strous GJ, Mol JA, Chesnokova V, Melmed S. WIP1 is a novel specific target for growth hormone action. iScience. 2023;26(11):108117. https://doi.org/10.1016/j.isci.2023.108117.CrossRefPubMedPubMedCentral

90.

Chesnokova V, Zonis S, Apostolou A, Estrada HQ, Knott S, Wawrowsky K, Michelsen K, Ben-Shlomo A, Barrett R, Gorbunova V, Karalis K, Melmed S. Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage. Cell Rep. 2021;37(11): 110068. https://doi.org/10.1016/j.celrep.2021.110068.CrossRefPubMedPubMedCentral

91.

Chesnokova V, Zonis S, Barrett RJ, Gleeson JP, Melmed S. Growth hormone induces colon DNA Damage Independent of IGF-1. Endocrinology. 2019;160(6):1439–47. https://doi.org/10.1210/en.2019-00132.CrossRefPubMedPubMedCentral

92.

Tripkovic I, Tripkovic A, Strnad M, Capkun V, Zekan L. Role of insulin-like growth factor-1 in colon cancerogenesis: a case-control study. Arch Med Res. 2007;38(5):519–25. https://doi.org/10.1016/j.arcmed.2007.01.012.CrossRefPubMed

93.

Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14(22):3484–9. https://doi.org/10.3748/wjg.14.3484.CrossRefPubMedPubMedCentral

94.

Terzolo M, Boccuzzi A. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab. 1996;81(6):2406–7. https://doi.org/10.1210/jcem.81.6.8964888.CrossRefPubMed

95.

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. https://doi.org/10.1016/S0140-6736(19)32319-0.CrossRefPubMed

96.

Parolin M, Dassie F, Russo L, Mazzocut S, Ferrata M, De Carlo E, Mioni R, Fallo F, Vettor R, Martini C, Maffei P. Guidelines versus real life practice: the case of colonoscopy in acromegaly. Pituitary. 2018;21(1):16–24. https://doi.org/10.1007/s11102-017-0841-7.CrossRefPubMed

97.

Lois K, Bukowczan J, Perros P, Jones S, Gunn M, James RA. The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary. 2015;18(4):568–74. https://doi.org/10.1007/s11102-014-0586-5.CrossRefPubMed

98.

Peng G, Li X, Zhou Y, Bai J, Hong P, Li W, Zhang Y, Zhang L, Liao Q, Liao M, Zhou L, Sun Z, Shen R, Zheng H, Long M. Clinical characteristics and associated factors of colonic polyps in acromegaly. Exp Clin Endocrinol Diabetes. 2022;130(11):714–22. https://doi.org/10.1055/a-1913-7900.CrossRefPubMedPubMedCentral

99.

Kojima Y, Suzuki S, Yamamura K, Kawasaki T, Yamamoto I. Identification of somatotrophs, mammosomatotrophs, and mammotrophs by sandwich cell immunoblot assay in GH-secreting adenomas and prolactinomas: correlations between the proportions of hormone secreting cells and tumor size. Endocr J. 2000;47(2):143–55. https://doi.org/10.1507/ENDOCRJ.47.143.CrossRefPubMed

100.

Renehan AG, Painter JE, Bell GD, et al. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf). 2005;62:323–30. https://doi.org/10.1111/j.1365-2265.2005.02217.x.CrossRefPubMed

101.

Renehan AG, O’Connell J, O’Halloran D, Shanahan F, Potten CS, O’Dwyer ST, Shalet SM. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res. 2003 Nov-Dec;35(11–12):712–25. https://doi.org/10.1055/s-2004-814150. Erratum in: Horm Metab Res. 2004 Jan;36(1):70–1

102.

Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, Colao A. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab. 2005;90(1):84–90. https://doi.org/10.1210/jc.2004-0240.CrossRefPubMed

103.

Iwamuro M, Yasuda M, Hasegawa K, Fujisawa S, Ogura-Ochi K, Sugihara Y, Harada K, Hiraoka S, Okada H, Otsuka F. Colonoscopy examination requires a longer time in patients with acromegaly than in other individuals. Endocr J. 2018;65(2):151–7. https://doi.org/10.1507/endocrj.EJ17-0322.CrossRefPubMed

104.

Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, Akker SA, Drake WM, Fairclough PD, Grossman AB, Jenkins PJ. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol. 2010;163(1):21–8. https://doi.org/10.1530/EJE-09-1080.CrossRefPubMed

105.

Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP, Besser GM. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3218–21. https://doi.org/10.1210/jcem.85.9.6806.CrossRefPubMed

106.

Kasuki L, Maia B, Gadelha MR. Acromegaly and Colorectal Neoplasm: An Update. Front Endocrinol (Lausanne). 2022;20(13): 924952. https://doi.org/10.3389/fendo.2022.924952.CrossRef

107.

Bogazzi F, Lombardi M, Scattina I, Urbani C, Marciano E, Costa A, Pepe P, Rossi G, Martino E. Comparison of colonoscopy and fecal occult blood testing as a first-line screening of colonic lesions in patients with newly diagnosed acromegaly. J Endocrinol Invest. 2010;33(8):530–3. https://doi.org/10.1007/BF03346642.CrossRefPubMed

108.

Brito JP, Davies L. Is there really an increased incidence of thyroid cancer? Curr Opin Endocrinol Diabetes Obes. 2014;21(5):405–8. https://doi.org/10.1097/MED.0000000000000094.CrossRefPubMed

109.

Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7. https://doi.org/10.1002/cncr.24416.CrossRefPubMed

110.

Haymart MR, Reyes-Gastelum D, Caoili E, Norton EC, Banerjee M. The relationship between imaging and thyroid cancer diagnosis and survival. Oncologist. 2020;25(9):765–71. https://doi.org/10.1634/theoncologist.2020-0159.CrossRefPubMedPubMedCentral

111.

Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225–34. https://doi.org/10.1016/S2213-8587(21)00027-9.CrossRefPubMed

112.

Vigneri R, Malandrino P, Vigneri P. The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol. 2015;27(1):1–7. https://doi.org/10.1097/CCO.0000000000000148.CrossRefPubMed

113.

Spricido IY, Feckinghaus CM, Silva RHM, Mesa Junior CO, Boguszewski CL. Prevalence of thyroid cancer in patients with acromegaly and non-growth hormone secreting pituitary adenomas: A prospective cross-sectional study. Growth Horm IGF Res. 2021;56: 101378. https://doi.org/10.1016/j.ghir.2021.101378.CrossRefPubMed

114.

Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K, Ito K. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh). 1989;121(1):112–20. https://doi.org/10.1530/acta.0.1210112.CrossRefPubMed

115.

Pidchenko NS, Krasnoselskyi MV, Mitriaieva NA, Grebenik LV, Astapieva OM, Grushka GV, Paskevych OI, Fedulenkova YY, Myroshnychenk MS. Insulin-like growth factors in the serum of patients with papillary thyroid cancer. Wiad Lek. 2021;74(8):1925–30.CrossRefPubMed

116.

Keskin FE, Ozkaya HM, Ferahman S, Haliloglu O, Karatas A, Aksoy F, Kadioglu P. The role of different molecular markers in papillary thyroid cancer patients with acromegaly. Exp Clin Endocrinol Diabetes. 2019;127(7):437–44. https://doi.org/10.1055/a-0629-9223.CrossRefPubMed

117.

Aydin K, Aydin C, Dagdelen S, Tezel GG, Erbas T. Genetic alterations in differentiated thyroid cancer patients with acromegaly. Exp Clin Endocrinol Diabetes. 2016;124(3):198–202. https://doi.org/10.1055/s-0035-1565061.CrossRefPubMed

118.

Kan S, Kizilgul M, Celik B, Beysel S, Caliskan M, Apaydin M, Ucan B, Cakal E. The effect of disease activity on thyroid nodules in patients with acromegaly. Endocr J. 2019;66(4):301–7. https://doi.org/10.1507/endocrj.EJ18-0502.CrossRefPubMed

119.

Natchev E, Vandeva S, Kovatcheva R, Kirilov G, Kalinov K, Zacharieva S. Thyroid gland changes in patients with acromegaly. Arch Endocrinol Metab. 2020;64(3):269–75. https://doi.org/10.20945/2359-3997000000247.CrossRefPubMedPubMedCentral

120.

Düğer H, Kızılgül M, Akhanlı P, Çalapkulu M, Bostan H, Hepşen S, Gül Ü, Sencar ME, Çakal E, Uçan B. The role of elastography in the assessment of thyroid nodules in acromegaly. Turk J Med Sci. 2023;53(1):303–9. https://doi.org/10.55730/1300-0144.5585.CrossRefPubMed

121.

Mo C, Zhong L. The effect of acromegaly on thyroid disease. Endocr J. 2023;70(11):1051–60. https://doi.org/10.1507/endocrj.EJ23-0356.CrossRefPubMed

122.

Kim HK, Lee JS, Park MH, Cho JS, Yoon JH, Kim SJ, Kang HC. Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. PLoS ONE. 2014;9(10): e110241. https://doi.org/10.1371/journal.pone.0110241.CrossRefPubMedPubMedCentral

123.

Zevallos JP, Hartman CM, Kramer JR, Sturgis EM, Chiao EY. Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: a study of the Veterans Affairs health care system. Cancer. 2015;121(5):741–6. https://doi.org/10.1002/cncr.29122.CrossRefPubMed

124.

Rogozinski A, Furioso A, Glikman P, Junco M, Laudi R, Reyes A, Lowenstein A. Thyroid nodules in acromegaly. Arq Bras Endocrinol Metabol. 2012;56(5):300–4. https://doi.org/10.1590/s0004-27302012000500004.CrossRefPubMed

125.

dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, dos Santos FM. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary. 2013;16(1):109–14. https://doi.org/10.1007/s11102-012-0383-y.CrossRefPubMed

126.

Reverter JL, Fajardo C, Resmini E, Salinas I, Mora M, Llatjós M, Sesmilo G, Rius F, Halperin I, Webb SM, Ricart V, Riesgo P, Mauricio D, Puig-Domingo M. Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS One. 2014;9(8):e104174. https://doi.org/10.1371/journal.pone.0104174.CrossRefPubMedPubMedCentral

127.

Varlamov EV, Niculescu DA, Banskota S, Galoiu SA, Poiana C, Fleseriu M. Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers. Endocr Connect. 2021;10(7):731–41. https://doi.org/10.1530/EC-21-0035.CrossRefPubMedPubMedCentral

128.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.CrossRef

129.

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7.CrossRefPubMed

130.

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. https://doi.org/10.1259/bjr.20211033.CrossRefPubMed

131.

Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: A 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015–20. https://doi.org/10.31557/APJCP.2019.20.7.2015.CrossRefPubMedPubMedCentral

132.

Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86. https://doi.org/10.1016/S0140-6736(12)61611-0.CrossRef

133.

Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4):515–23. https://doi.org/10.1002/cncr.31840.CrossRefPubMed

134.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American cancer society/american society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73. https://doi.org/10.3322/caac.21319.CrossRefPubMed

135.

US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, Davis EM, Jaén CR, Krousel-Wood M, Lee S, Li L, Mangione CM, Rao G, Ruiz JM, Stevermer JJ, Tsevat J, Underwood SM, Wiehe S. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024 Jun 11;331(22):1918–1930. https://doi.org/10.1001/jama.2024.5534. Erratum in: JAMA. 2024 Sep 30. https://doi.org/10.1001/jama.2024.19851.

136.

Schünemann HJ, Lerda D, Dimitrova N, Alonso-Coello P, Gräwingholt A, Quinn C, Follmann M, Mansel R, Sardanelli F, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Warman S, European Commission Initiative on Breast Cancer Contributor Group. Saz-Parkinson Z Methods for development of the european commission initiative on breast cancer guidelines: recommendations in the era of guideline transparency. Ann Intern Med. 2019;171(4):273–80. https://doi.org/10.7326/M18-3445.CrossRefPubMed

137.

Borrelli C, Cohen S, Duncan A, Given-Wilson R, Jenkins J, Kearins O, et al. NHS Breast Screening Programme. Clinical guidance for breast cancer screening assessment. Fourth edition Nov 2016.

138.

Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26(4):481–512. https://doi.org/10.1111/j.1365-2265.1987.tb00805.x.CrossRefPubMed

139.

Murphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK, Smith-Byrne K, Fensom G, Perez-Cornago A, Travis RC, Key TJ, Gunter MJ. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol. 2020;31(5):641–9. https://doi.org/10.1016/j.annonc.2020.01.066.CrossRefPubMed

140.

Tagliafico A, Calabrese M, Tagliafico G, Resmini E, Martinoli C, Rebora A, Colao A, Pivonello R, Ferone D. Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. Eur J Endocrinol. 2011;164(3):335–40. https://doi.org/10.1530/EJE-10-0896.CrossRefPubMed

141.

Akhanlı P, Hepşen S, Uçan B, Düğer H, Bostan H, Kızılgül M, Sencar ME, Çakal E. The evaluation of breast findings detected through different visualisation techniques in acromegaly patients — a retrospective study. Turk J Med Sci. 2021;51(6):3073–81. https://doi.org/10.3906/sag-2105-35.CrossRefPubMedPubMedCentral

142.

Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR, Pankratz VS. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res. 2007;9(6):217. https://doi.org/10.1186/bcr1829.CrossRefPubMedPubMedCentral

143.

Wanders JO, Holland K, Veldhuis WB, Mann RM, Pijnappel RM, Peeters PH, van Gils CH, Karssemeijer N. Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat. 2017;162(1):95–103. https://doi.org/10.1007/s10549-016-4090-7.CrossRefPubMed

144.

Giorgi Rossi P, Djuric O, Hélin V, Astley S, Mantellini P, Nitrosi A, Harkness EF, Gauthier E, Puliti D, Balleyguier C, Baron C, Gilbert FJ, Grivegnée A, Pattacini P, Michiels S, Delaloge S. Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk. Sci Rep. 2021;11(1):19884. https://doi.org/10.1038/s41598-021-99433-3.CrossRefPubMedPubMedCentral

145.

Mann RM, Athanasiou A, Baltzer PAT, Camps-Herrero J, Clauser P, Fallenberg EM, Forrai G, Fuchsjäger MH, Helbich TH, Killburn-Toppin F, Lesaru M, Panizza P, Pediconi F, Pijnappel RM, Pinker K, Sardanelli F, Sella T, Thomassin-Naggara I, Zackrisson S, Gilbert FJ, Kuhl CK, European Society of Breast Imaging (EUSOBI). Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol. 2022;32(6):4036–45. https://doi.org/10.1007/s00330-022-08617-6.CrossRefPubMedPubMedCentral

146.

Boguszewski CL, Ayuk J. Management of endocrine disease: Acromegaly and cancer: an old debate revisited. Eur J Endocrinol. 2016;175(4):R147–56. https://doi.org/10.1530/EJE-16-0178.CrossRefPubMed

147.

Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998;49(4):441–5. https://doi.org/10.1046/j.1365-2265.1998.00536.x.CrossRefPubMed

148.

Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22–32. https://doi.org/10.1007/s11102-016-0772-8.CrossRefPubMed

149.

Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5–12.PubMedPubMedCentral

150.

Risør BW, Tayyari Dehbarez N, Fredsøe J, Sørensen KD, Pedersen BG. Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the primary blood test in the prostate cancer diagnostic pathway: a decision tree approach. Appl Health Econ Health Policy. 2022;20(6):867–80. https://doi.org/10.1007/s40258-022-00741-0.CrossRefPubMedPubMedCentral

151.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, ERSPC Investigators. Screening and prostate cancer mortality: results of the european randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35. https://doi.org/10.1016/S0140-6736(14)60525-0.CrossRefPubMedPubMedCentral

152.

Perry JK, Wu ZS, Mertani HC, Zhu T, Lobie PE. Tumour-derived human growth hormone as a therapeutic target in oncology. Trends Endocrinol Metab. 2017;28(8):587–96. https://doi.org/10.1016/j.tem.2017.05.003.CrossRefPubMed

153.

Krawitt LN. Giant prostatic cancer with acromegaly. J Urol. 1973;110(4):441–2. https://doi.org/10.1016/s0022-5347(17)60244-1.CrossRefPubMed

154.

Colao A, Marzullo P, Spiezia S, Ferone D, Giaccio A, Cerbone G, Pivonello R, Di Somma C, Lombardi G. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab. 1999;84(6):1986–91. https://doi.org/10.1210/jcem.84.6.5776.CrossRefPubMed

155.

Corrêa LL, Balarini Lima GA, Cavallieri SA, Miranda LC, Gadelha MR. Prostatic disorders in acromegalic patients experience of a Brazilian center. Int Braz J Urol. 2013;39(3):393–401. https://doi.org/10.1590/S1677-5538.IBJU.2013.03.13.CrossRefPubMed

156.

Colao A, Marzullo P, Spiezia S, Lombardi G. Acromegaly and prostate cancer. Growth Horm IGF Res. 2000;10(Suppl):S37-8. https://doi.org/10.1016/s1096-6374(00)90018-2.CrossRefPubMed

Title: Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries
Authors: Luigi Demarchis
Sabrina Chiloiro
Antonella Giampietro
Laura De Marinis
Antonio Bianchi
Maria Fleseriu
Alfredo Pontecorvi
Publication date: 15-03-2025
Publisher: Springer US
Keywords: Acromegaly
Diagnostics in Oncology
Diagnostics in Endocrinology
Thyroid Cancer
Colon Cancer
Breast Cancer
Thyroid Cancer
Prostate Cancer
Published in: Reviews in Endocrine and Metabolic Disorders
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-025-09957-6

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content

At a glance: The STEP trials